First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...
The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...
Abbott, a global healthcare leader, announced it has received CE Mark and Health Canada approval for its Amplatzer Steerable Delivery Sheath, which is used with the company's market-leading Amplatzer ...
- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation - New delivery ...
The FDA has issued its most serious label to an Abbott recall of delivery catheters used for a specific minimally invasive heart surgery, due to a risk of introducing dangerous air bubbles into the ...
PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...
A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results